Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Samuel T Workenhe"'
Autor:
Jonathan Bramson, Karen L Mossman, Samuel T Workenhe, Jordon M Inkol, Michael J Westerveld, Shayla G Verburg, Scott R Walsh, Jodi Morrison, Sarah M Worfolk, Kaslyn LF Kallio, Noah J Phippen, Rebecca Burchett, Yonghong Wan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background Initiation of antitumor immunity is reliant on the stimulation of dendritic cells (DCs) to present tumor antigens to naïve T cells and generate effector T cells that can kill cancer cells. Induction of immunogenic cell death after certain
Externí odkaz:
https://doaj.org/article/36f11ec2dbd04f1a8f858295eed90785
Autor:
Huy-Dung Hoang, Aida Said, Nasana Vaidya, Victoria H Gilchrist, Kyle Malone, Usha Kabilan, Serena Topshee, Xiao Xiang, An-Dao Yang, David Olagnier, Karen Mossman, Shawn T Beug, Seyed Mehdi Jafarnejad, Samuel T Workenhe, Tyson E Graber, Tommy Alain
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background Transgenes deliver therapeutic payloads to improve oncolytic virus immunotherapy. Transgenes encoded within oncolytic viruses are designed to be highly transcribed, but protein synthesis is often negatively affected by viral infection, com
Externí odkaz:
https://doaj.org/article/a6f957f1406d4b8b8ac61e2d28561a27
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
The immune system can recognize tumor cells to mount antigen-specific T cell response. Central to the establishment of T cell-mediated adaptive immunity are the inflammatory events that facilitate antigen presentation by stimulating the expression of
Externí odkaz:
https://doaj.org/article/65b7dfb795124825b195afcc11966c59
PDF file - 205K, Supplementary figure 1. Addition of MTX does not enhance KM100 virus replication
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2b32c4a240eccffa768fa3a18954d46
https://doi.org/10.1158/2326-6066.22536214
https://doi.org/10.1158/2326-6066.22536214
PDF file - 332K, Supplementary figure 3. Antigen presenting cells infiltrating treated tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0633a1ecff59bccf36dc29dd933f9710
https://doi.org/10.1158/2326-6066.22536208
https://doi.org/10.1158/2326-6066.22536208
Although antitumor activity of herpes simplex virus 1 (HSV-1) ICP0 null oncolytic vectors has been validated in murine breast cancer models, oncolytic virus treatment alone is insufficient to break immune tolerance. Thus, we investigated enhancing ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::548b632f273c7f0643a47c7dd17fb0d6
https://doi.org/10.1158/2326-6066.c.6548068.v1
https://doi.org/10.1158/2326-6066.c.6548068.v1
PDF file - 463K, Supplementary figure 2. Percent survival and fold changes in tumor volume after treatment with KM100 and/or 1 microM MTX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01f288614a062b5f07a26486ab3c19db
https://doi.org/10.1158/2326-6066.22536211
https://doi.org/10.1158/2326-6066.22536211
Autor:
Danielle Harrington, Yonghong Wan, Alyssa Vito, Ana L. Portillo, Nader El-Sayes, Samuel T Workenhe, Ian P. MacFawn, Karen L. Mossman, Omar Salem, Ali A. Ashkar, Tullia C. Bruno, Brad H. Nelson, Katy Milne
Publikováno v:
Communications Biology
Communications Biology, Vol 4, Iss 1, Pp 1-19 (2021)
Communications Biology, Vol 4, Iss 1, Pp 1-19 (2021)
Triple negative breast cancer holds a dismal clinical outcome and as such, patients routinely undergo aggressive, highly toxic treatment regimens. Clinical trials for TNBC employing immune checkpoint blockade in combination with chemotherapy show mod
Publikováno v:
OncoImmunology
OncoImmunology, Taylor & Francis, 2021, 10 (1), pp.1893466. ⟨10.1080/2162402x.2021.1893466⟩
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
OncoImmunology, Taylor & Francis, 2021, 10 (1), pp.1893466. ⟨10.1080/2162402x.2021.1893466⟩
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
International audience; The immune system can recognize tumor cells to mount antigen-specific T cell response. Central to the establishment of T cell-mediated adaptive immunity are the inflammatory events that facilitate antigen presentation by stimu